Search

Your search keyword '"Kang, Jaewon"' showing total 21 results
Start Over Author "Kang, Jaewon" Publisher elsevier bv
21 results on '"Kang, Jaewon"'

9. Nucleocapsid-specific antibody function is associated with therapeutic benefit from Covid-19 Convalescent plasma therapy

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Herman, Jonathan D, Wang, Chuangqi, Burke, John Stephen, Zur, Yonatan, Compere, Hacheming, Kang, Jaewon, Macvicar, Ryan, Taylor, Sabian, Shin, Sally, Frank, Ian, Siegel, Don, Tebas, Pablo, Choi, Grace H, Shaw, Pamela A, Yoon, Hyunah, Pirofski, Liise-anne, Julg, Boris D, Bar, Katharine J, Lauffenburger, Douglas, Alter, Galit, Massachusetts Institute of Technology. Department of Biological Engineering, Herman, Jonathan D, Wang, Chuangqi, Burke, John Stephen, Zur, Yonatan, Compere, Hacheming, Kang, Jaewon, Macvicar, Ryan, Taylor, Sabian, Shin, Sally, Frank, Ian, Siegel, Don, Tebas, Pablo, Choi, Grace H, Shaw, Pamela A, Yoon, Hyunah, Pirofski, Liise-anne, Julg, Boris D, Bar, Katharine J, Lauffenburger, Douglas, and Alter, Galit

Abstract

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results. Although antibody neutralization is the predominant approach to benchmarking CCP efficacy, CCP may also influence the evolution of the endogenous antibody response. Using systems serology to comprehensively profile severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) functional antibodies of hospitalized people with COVID-19 enrolled in a randomized controlled trial of CCP (ClinicalTrials.gov: NCT04397757), we find that the clinical benefits of CCP are associated with a shift toward reduced inflammatory Spike (S) responses and enhanced nucleocapsid (N) humoral responses. We find that CCP has the greatest clinical benefit in participants with low pre-existing anti-SARS-CoV-2 antibody function and that CCP-induced immunomodulatory Fc glycan profiles and N immunodominant profiles persist for at least 2 months. We highlight a potential mechanism of action of CCP associated with durable immunomodulation, outline optimal patient characteristics for CCP treatment, and provide guidance for development of a different class of COVID-19 hyperinflammation-targeting antibody therapeutic agents.

Published
2023

10. Antibody effector functions are associated with protection from respiratory syncytial virus

Author

Bartsch, Yannic C., primary, Cizmeci, Deniz, additional, Kang, Jaewon, additional, Zohar, Tomer, additional, Periasamy, Sivakumar, additional, Mehta, Nickita, additional, Tolboom, Jeroen, additional, Van der Fits, Leslie, additional, Sadoff, Jerry, additional, Comeaux, Christy, additional, Callendret, Benoit, additional, Bukreyev, Alexander, additional, Lauffenburger, Douglas A., additional, Bastian, Arangassery Rosemary, additional, and Alter, Galit, additional

Published
2022
Full Text
View/download PDF

11. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy

Author

Herman, Jonathan D., primary, Wang, Chuangqi, additional, Burke, John Stephen, additional, Zur, Yonatan, additional, Compere, Hacheming, additional, Kang, Jaewon, additional, Macvicar, Ryan, additional, Taylor, Sabian, additional, Shin, Sally, additional, Frank, Ian, additional, Siegel, Don, additional, Tebas, Pablo, additional, Choi, Grace H., additional, Shaw, Pamela A., additional, Yoon, Hyunah, additional, Pirofski, Liise-anne, additional, Julg, Boris D., additional, Bar, Katharine J., additional, Lauffenburger, Douglas, additional, and Alter, Galit, additional

Published
2022
Full Text
View/download PDF

16. A Role for Nucleocapsid-Specific Antibody Function in COVID-19 Convalescent Plasma Therapy

Author

Herman, Jonathan D., primary, Wang, Chuangqi, additional, Burke, John Stephen, additional, Zur, Yonatan, additional, Compere, Hacheming, additional, Kang, Jaewon, additional, Macvicar, Ryan, additional, Shin, Sally, additional, Frank, Ian, additional, Siegel, Don, additional, Tebas, Pablo, additional, Choi, Grace H., additional, Shaw, Pamela A., additional, Yoon, Hyunah, additional, Pirofski, Liise-anne, additional, Juelg, Boris D., additional, Bar, Kathrine, additional, Lauffenburger, Douglas, additional, and Alter, Galit, additional

Published
2022
Full Text
View/download PDF

17. Resilient Fc-Effector Functions Across SARS-CoV-2 Variants of Concern Following mRNA-1273 Vaccination

Author

Kaplonek, Paulina, primary, Fischinger, Stephanie, additional, Cizmeci, Deniz, additional, Bartsch, Yannic C., additional, Kang, Jaewon, additional, Burke, John S., additional, Shin, Sally A., additional, Dayal, Diana, additional, Martin, Patrick, additional, Mann, Colin, additional, Amanat, Fatima, additional, Julg, Boris, additional, Nilles, Eric J., additional, Musk, Elon R., additional, Menon, Anil S., additional, Krammer, Florian, additional, Saphire, Erica Ollmann, additional, Carfi, Andrea, additional, and Alter, Galit, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results